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SI Text
RNA-Sequencing (RNA-Seq) Processing Needs to Take the Presence of
Two Transcriptomes into Account. Initial attempts to map and quan-
tify RNA-seq data using the commonly used software packages
TopHat and Cufflinks (1) using just the human genome as a
reference resulted in unsatisfactory results (which was demon-
strated by control quantitative reverse transcription-PCR (qRT-
PCR) experiments) likely due to the presence of significant
amounts of host RNA in the libraries and the extensive sequence
homology between highly conserved mouse and human genes.
We investigated this by comparing the mapping efficiencies of the
tumor samples to the human genome (hg19) to the mouse (mm9).
The ratio between the mapping percentages to hg19 and mm9 is
reflective of the tumor composition and was found to lay typically
between 1.3 and 1.4, suggesting some 40% of the tumor mRNA to
be mouse derived (Table S2). For comparison the ratio for the
parent A549 cell line from an in vitro experiment was determined
as 7.0, while that of a control mouse spleen sample was 0.12. This
prompted us to devise the computational pipeline that simulta-
neously maps to both species’ transcriptome as described in the
main text.
Affected Genes Listed in Table 1 (Main Text). ATM: Official symbol: ATM
and name: Ataxia telangiectasia mutated. The protein encoded by
this gene belongs to the PI3/PI4-kinase family. This protein is an
important cell cycle checkpoint kinase that phosphorylates; thus,
it functions as a regulator of a wide variety of downstream pro-
teins, including tumor suppressor proteins p53 and BRCA1,
checkpoint kinase CHK2, checkpoint proteins RAD17 and
RAD9, and DNA repair protein NBS1. This protein and the clo-
sely related kinase ataxia telangiectasia and Rad3 related are
thought to be master controllers of cell cycle checkpoint signaling
pathways that are required for cell response to DNA damage and
for genome stability. Mutations in this gene are associated with
ataxia telangiectasia, an autosomal recessive disorder. [provided
by NCBI reference sequence (refSeq), Aug. 2010].
CCL2: Official symbol: CCL2 and name: Chemokine (C—C motif) ligand
2. This gene is one of several cytokine genes clustered on the
q-arm of chromosome 17. Cytokines are a family of secreted pro-
teins involved in immunoregulatory and inflammatory processes.
The protein encoded by this gene is structurally related to the
chemokine (C-X-C motif) subfamily of cytokines. Members of
this subfamily are characterized by two cysteines separated by
a single amino acid. This cytokine displays chemotactic activity
for monocytes and basophils but not for neutrophils or eosino-
phils. It has been implicated in the pathogenesis of diseases char-
acterized by monocytic infiltrates, like psoriasis, rheumatoid
arthritis, and atherosclerosis. It binds to chemokine receptors
CCR2 and CCR4. (provided by refSeq, July 2008).
EGFR: Official symbol: EGFR and name: Epidermal growth factor recep-
tor. The protein encoded by this gene is a transmembrane glyco-
protein that is a member of the protein kinase superfamily. This
protein is a receptor for members of the epidermal growth factor
family. EGFR is a cell surface protein that binds to epidermal
growth factor. Binding of the protein to a ligand induces receptor
dimerization and tyrosine autophosphorylation and leads to cell
proliferation. Mutations in this gene are associated with lung can-
cer. Multiple alternatively spliced transcript variants that encode
different protein isoforms have been found for this gene. (pro-
vided by refSeq, July 2010).
MMP28: Official symbol: MMP28 and name: Matrix metallopeptidase
28.Proteins of the matrix metalloproteinase family are involved in
the breakdown of extracellular matrix for both normal physiolo-
gical processes, such as embryonic development, reproduction
and tissue remodeling, and disease processes, such as asthma and
metastasis. This gene encodes a secreted enzyme that degrades
casein. Its expression pattern suggests that it plays a role in tissue
homeostasis and in wound repair. Transcript variants encoding
different isoforms have been described. (provided by refSeq,
March 2010).
NPTX1: Official symbol: NPTX1 and name: Neuronal _Pentraxin I.
NPTX1 is a member of the neuronal pentraxin gene family. Neu-
ronal pentraxin 1 is similar to the rat NP1 gene that encodes a
binding protein for the snake venom toxin taipoxin. Human
NPTX1 mRNA is exclusively localized to the nervous system.
(provided by refSeq, July 2008).
ROBO1: Official symbol: ROBO1 and name: Roundabout, axon guidance
receptor, homolog 1 (drosophila). Bilateral symmetric nervous sys-
tems have special midline structures that establish a partition be-
tween the two mirror image halves. Some axons project toward
and across the midline in response to long-range chemoattrac-
tants emanating from the midline. The product of this gene is
a member of the immunoglobulin gene superfamily and encodes
an integral membrane protein that functions in axon guidance
and neuronal precursor cell migration. This receptor is activated
by SLIT-family proteins, resulting in a repulsive effect on glioma
cell guidance in the developing brain. A related gene is located at
an adjacent region on chromosome 3. Multiple transcript variants
encoding different isoforms have been found for this gene. (pro-
vided by refSeq, March 2009).
SERPINE1: Official symbol: SERPINE1 and name: Serpin peptidase inhi-
bitor, clade E (nexin, plasminogen activator inhibitor type 1), member
1. This gene encodes a member of the serine proteinase inhibitor
(serpin) superfamily. This member is the principal inhibitor of
tissue plasminogen activator and urokinase, and hence is an in-
hibitor of fibrinolysis. Defects in this gene are the cause of plas-
minogen activator inhibitor-1 deficiency (PAI-1 deficiency), and
high concentrations of the gene product are associated with
thrombophilia. Alternatively spliced transcript variants encoding
different isoforms have been found for this gene. (provided by
refSeq, Sep. 2009).
1. Trapnell C, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals
unannotated transcripts and isoform switching during cell differentiation. Nat Bio-
technol 28:511–515.
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Fig. S1. (A) In vitro cytotoxicity of 1 vs 2 against the A549-luc-C8 cell line, measured employing the sulforhodamine B (SRB) assay. For full chemical structures of
1 and 2 see Fig. 1 of the main text. (B) Uptake of 3 in A549-luc-C8, measured by confocal microscopy (LSM 5 Exciter). Cells were incubated with Py-Im polyamide
3 at 1 uM final concentration for 12 h, washed once with PBS and imaged.
Fig. S2. Internal standard 4, used for calibration of analytical HPLC.
Fig. S3. (A) Vehicle group. (B) Treated with 1 as outlined in the experimental section. Averaged luciferase output values with the associated standard devia-
tions are ð3.0 1.7Þ × 105 for vehicle and ð8.8 5.1Þ × 105 for treated.
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Fig. S4. Correlation between single reads (1 × 50 nt) and paired-end reads (2 × 100 nt) sequencing for tumors obtained from vehicle- (Left) and Py-Im poly-
amide-treated (Right) animals.
Table S1. Treatment schedule for SCID-beige animals with
Py-Im polyamide 1. A549-luc-C8 were engrafted at 5 × 106
cells in 200 μLmedia per animal. Compound 1was injected
at 120 nmol∕animal in 200 μL vehicle (PBS∕DMSO, 4∶1) per
injection
Day 0 1 2 3 4 5 6 7 8 9 10
Engraft X
Treat X X X X X
Weigh X X
Image X
Harvest X
Table S2. Mapping percentages of the A549-luc-C8 xenograft-derived RNA-seq
reads to hg19 and mm9 (entries 1–6). Mapping percentages of the parent A549
cell line (entry 7) and SCID-bg mouse spleen mRNA (entry 8) are given for
reference. All RNA-seq experiments were conducted with 1 × 50 nt (single reads)
Entry Condition No. of reads % hg19 % mm9 [% hg19]/[% mm9]
1 XenoVehicle 1 35478968 59.5 42.9 1.39
2 Xeno Vehicle 2 50839514 36.5 27.5 1.33
3 Xeno Vehicle 3 50150429 59.2 46.3 1.28
4 Xeno Treated 1 54437744 59.5 43.3 1.37
5 Xeno Treated 2 49087273 39.7 28.9 1.38
6 Xeno Treated 3 34553534 60.4 44.4 1.36
7 A549 in vitro 35187689 83.0 11.9 6.97
8 SCID-bg spleen 34932537 11.9 95.8 0.12
Table S3. qRT-PCR measurements of expression
changes of genes shown in Fig. 5 (A549-luc-C8 cell
line); brackets indicate gene upregulation upon
treatment. Xenograft: three independent
experiments with N ¼ 5 animals per treatment
condition (vehicle vs 1) were averaged. Cell culture:
where indicated, the cells were incubated with Py-Im
polyamide 1 at 10μM final concentration in 0.1%
DMSO as vehicle
Gene Xenograft Culture, 48 h Culture, 72 h
ATM 1.5 ± 0.2 1.9 ± 0.2 2.5 ± 0.3
NPTX1 3.3 ± 0.6 2.6 ± 0.5 3.5 ± 1.15
ROBO1 1.5 ± 0.2 3.3 ± 0.5 4.5 ± 0.7
MMP28 [1.5 ± 0.3] 1.1 ± 0.75 1.1 ± 0.7
EGFR 1.2 ± 0.2 1.9 ± 0.2 2.8 ± 0.3
CCL2 2.3 ± 0.4 2.2 ± 0.3 4.4 ± 0.45
SERPINE1 2.0 ± 0.2 8.3 ± 1.0 15.7 ± 1.65
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